9-ING-41 in Patients With Advanced Cancers
Trial details
- Registry ID
- NCT03678883
- Drugs studied
- 9-ING-41, Carboplatin., Doxorubicin., Gemcitabine - 21 day cycle and 5 more
TrialRedline tracks 2 clinical trials sponsored by Actuate Therapeutics Inc.: 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| 9-ING-41 in Patients With Advanced CancersNCT03678883 | 9-ING-41, Carboplatin., Doxorubicin., Gemcitabine - 21 day cycle and 5 more | Active not recruiting | 2026-06Estimated |
| Actuate 1901: 9-ING-41 in MyelofibrosisNCT04218071 | 9-ING-41, Ruxolitinib | Completed | 2022-10-13Actual |
Names as written in the registry records.
NCT03678883 · Actuate Therapeutics Inc.
Before: Jan 2025. After: Jun 2026.